GleamWall
中文EN

IBRX ImmunityBio, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1326110 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY121.2%
TTM net income YoY-218.3%
TTM EPS YoY-158.5%
Revenue 3-yr CAGR589.9%
Net income 3-yr CAGR—

Margins

Gross margin98.8%
Operating margin-150.2%
Net margin-607.8%
FCF margin-162.5%
EBITDA margin-141.1%

Returns

ROE—
ROA-196.7%
ROIC (approx.)—
Asset turnover0.32x

Leverage & solvency

Liabilities / assets288.0%
Debt / equity—
Current ratio4.27x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.26x
Accruals ratio-145.7%
Payout ratio—
Capex / revenue5.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$48.84M$51.24M$44.21M$38.28M$32.06M$26.43M$16.52M$7.55M
Cost of revenue$1.29M$298,000$238,000$382,000$177,000$136,000$58,000$0
Gross profit$47.55M$50.94M$43.97M$37.90M$31.88M$26.29M$16.46M$7.55M
R&D expense———————$35.22M
SG&A expense———————$41.73M
Operating income-$77.99M-$61.70M-$69.79M-$64.68M-$55.63M-$71.28M-$64.43M-$69.40M
Interest expense———$14.84M$15.26M$15.47M$15.31M$26.02M
Pretax income-$184.56M-$230.39M-$632.79M-$62.09M-$67.31M-$92.31M-$129.90M-$59.18M
Income tax$0$0$9,000-$135,000-$35,000$269,000-$234,000$0
Net income-$184.55M-$230.38M-$632.78M-$61.94M-$67.25M-$92.56M-$129.65M-$59.16M
EBITDA-$74.10M-$57.29M-$65.41M-$60.82M-$52.23M-$67.89M-$60.60M-$65.26M
EPS (basic)-0.17-0.22-0.62—-0.07-0.10-0.15—
EPS (diluted)-0.18-0.22-0.62—-0.07-0.10-0.15—
Weighted avg. shares (diluted)1.06B1.05B1.03B—946.60M888.22M853.16M—
Balance sheet
Cash & equivalents$45.08M$75.67M$205.19M$88.33M$60.24M$137.66M$60.66M$143.43M
Short-term investments$289.25M$281.70M$175.69M$154.48M$197.57M$16.00M$931,000$6.38M
Receivables$53.60M$53.47M$43.27M$42.57M$32.02M$22.13M$17.03M$2.36M
Inventory$6,000$1.94M$547,000$910,000$6.70M$6.64M$8.44M$8.27M
Current assets$418.79M$438.98M$452.95M$314.88M$329.50M$208.13M$109.16M$184.59M
PP&E, net$115.05M$114.22M$112.78M$114.26M$129.60M$133.00M$135.27M$137.09M
Goodwill——$910,000$910,000$910,000$910,000$910,000$910,000
Intangibles——$11.91M$12.99M$13.53M$13.51M$14.02M$14.53M
Total assets$609.39M$628.50M$646.64M$501.90M$518.99M$402.08M$303.76M$382.93M
Current liabilities$98.09M$76.73M$67.95M$61.75M$57.13M$50.64M$49.20M$54.94M
Short-term debt——$884,000$1.75M$2.60M——$1.25M
Total liabilities$1.75B$1.67B$1.52B$1.00B$1.04B$971.89M$894.24M$871.06M
Shareholders' equity-$1.15B-$1.05B-$870.01M-$500.47M-$524.32M-$570.75M-$591.43M-$489.10M
Shares outstanding1.06B1.05B1.05B1.01B984.97M915.63M853.56M852.90M
Cash flow statement
Operating cash flow-$75.33M-$66.49M-$75.36M-$70.38M-$68.91M-$79.75M-$85.91M-$85.14M
Capital expenditure$2.93M$3.52M$1.78M$903,000$741,000$1.08M$1.12M$2.11M
Free cash flow-$78.26M-$70.01M-$77.14M-$71.28M-$69.65M-$80.83M-$87.03M-$87.25M
Investing cash flow-$8.04M-$107.47M-$31.65M$43.57M-$181.36M-$16.14M$4.13M$9.83M
Financing cash flow$53.03M$44.44M$223.93M$54.89M$173.52M$172.81M-$982,000$106.93M
Depreciation & amortization$3.89M$4.41M$4.38M$3.87M$3.40M$3.40M$3.83M$4.14M
Stock-based compensation$8.72M$8.52M$8.17M$8.75M$8.88M$9.65M$9.54M$9.04M

Free plan shows the latest 8 periods; Pro shows all 51 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.